Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.69
$0.00070.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.71M | 7.05M | 7.10M | 7.84M | 8.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.89M | 14.25M | 16.14M | 16.92M | 16.81M |
| Operating Income | -13.89M | -14.25M | -16.14M | -16.92M | -16.81M |
| Income Before Tax | -13.61M | -13.90M | -15.76M | -16.37M | -16.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.61 | -13.90 | -15.76 | -16.37 | -16.10 |
| Earnings from Discontinued Operations | -- | -- | -16.90K | -16.90K | -182.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.61M | -13.90M | -15.78M | -16.39M | -16.28M |
| EBIT | -13.89M | -14.25M | -16.14M | -16.92M | -16.81M |
| EBITDA | -13.24M | -13.60M | -15.49M | -16.28M | -16.16M |
| EPS Basic | -10.72 | -12.82 | -14.83 | -14.83 | -14.00 |
| Normalized Basic EPS | -6.70 | -8.01 | -9.25 | -9.25 | -8.65 |
| EPS Diluted | -10.72 | -12.82 | -14.83 | -14.83 | -14.00 |
| Normalized Diluted EPS | -6.70 | -8.01 | -9.25 | -9.25 | -8.65 |
| Average Basic Shares Outstanding | 5.55M | 4.38M | 4.36M | 4.57M | 4.83M |
| Average Diluted Shares Outstanding | 5.55M | 4.38M | 4.36M | 4.57M | 4.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |